Vivos Therapeutics (VVOS) Income from Continuing Operations (2020 - 2026)
Vivos Therapeutics (VVOS) posted quarterly Income from Continuing Operations of 7751000.0 for Q1 2026, down 100.6% year-over-year from 1302168000.0 in Q1 2025, and down 11.46% quarter-over-quarter from 6954000.0 in Q4 2025.
Vivos Therapeutics (VVOS) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Vivos Therapeutics (VVOS) has reported Income from Continuing Operations for 7 consecutive years, with 7751000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 100.6% year-over-year to 7751000.0; the TTM figure through Mar 2026 stood at 25118000.0 (down 122.38% YoY), while the FY2025 annual figure was 21230000.0, down 89.66% from the prior year.
- Income from Continuing Operations slipped to 7751000.0 in Q1 2026 per VVOS's latest filing, from 6954000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 9367000.0 in Q4 2023 and bottomed at 7751000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 3769352.94 across 5 years, with a median of 5013000.0 in 2025.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations soared 251.35% — and 2025, when it slumped 159.74%.
- Vivos Therapeutics' Income from Continuing Operations stood at 6189000.0 in 2022, then jumped by 251.35% to 9367000.0 in 2023, then plunged by 130.8% to 2885000.0 in 2024, then slumped by 141.04% to 6954000.0 in 2025, then fell by 11.46% to 7751000.0 in 2026.
- Business Quant data shows VVOS's Income from Continuing Operations at 7751000.0 in Q1 2026, 6954000.0 in Q4 2025, and 5400000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 905.00 Mn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 241.40 Mn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 574.00 Mn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 1.04 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Vivos Therapeutics | 4.94 Mn | 3.14 Mn | 2.95 Mn | -5.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.75 Mn |
| Dec 31, 2025 | -6.95 Mn |
| Sep 30, 2025 | -5.40 Mn |
| Jun 30, 2025 | -5.01 Mn |
| Mar 31, 2025 | -3.86 Mn |
| Dec 31, 2024 | -2.89 Mn |
| Sep 30, 2024 | -2.62 Mn |
| Jun 30, 2024 | -1.93 Mn |
| Mar 31, 2024 | -3.76 Mn |
| Dec 31, 2023 | 9.37 Mn |
| Sep 30, 2023 | -2.09 Mn |
| Jun 30, 2023 | -5.53 Mn |
| Mar 31, 2023 | -1.70 Mn |
| Dec 31, 2022 | -6.19 Mn |
| Sep 30, 2022 | -5.43 Mn |
| Jun 30, 2022 | -6.99 Mn |
| Mar 31, 2022 | -5.33 Mn |
| Dec 31, 2021 | -7.41 Mn |
| Sep 30, 2021 | -5.45 Mn |
| Jun 30, 2021 | -4.04 Mn |